Ibrutinib has 'unprecedented' impact on mantle cell lymphoma
Sunday, December 16, 2012 - 11:00
in Physics & Chemistry
An international study of ibrutinib in people with relapsed or refractory mantle cell lymphoma (MCL) continues to show unprecedented and durable results with few side effects.